A detailed history of Deka Bank Deutsche Girozentrale transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Deka Bank Deutsche Girozentrale holds 50,000 shares of BEAM stock, worth $1.26 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
50,000
Previous 50,000 -0.0%
Holding current value
$1.26 Million
Previous $1.7 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$23.01 - $32.46 $115,050 - $162,300
-5,000 Reduced 9.09%
50,000 $1.2 Million
Q1 2023

Apr 24, 2023

BUY
$30.15 - $48.79 $301,500 - $487,900
10,000 Added 22.22%
55,000 $1.66 Million
Q4 2022

Feb 01, 2023

BUY
$36.73 - $51.6 $734,599 - $1.03 Million
20,000 Added 80.0%
45,000 $1.74 Million
Q3 2022

Nov 02, 2022

BUY
$39.79 - $70.31 $437,690 - $773,410
11,000 Added 78.57%
25,000 $1.2 Million
Q2 2022

Aug 03, 2022

SELL
$29.86 - $62.36 $53,748 - $112,248
-1,800 Reduced 11.39%
14,000 $566,000
Q1 2022

Apr 28, 2022

BUY
$53.73 - $82.16 $5,373 - $8,216
100 Added 0.64%
15,800 $939,000
Q4 2021

Feb 02, 2022

BUY
$68.02 - $99.06 $27,208 - $39,624
400 Added 2.61%
15,700 $1.24 Million
Q3 2021

Oct 22, 2021

BUY
$84.37 - $133.6 $843,700 - $1.34 Million
10,000 Added 188.68%
15,300 $1.33 Million
Q2 2021

Aug 05, 2021

SELL
$64.12 - $128.71 $1.03 Million - $2.06 Million
-16,000 Reduced 75.12%
5,300 $587,000
Q1 2021

Apr 28, 2021

BUY
$71.28 - $120.75 $92,664 - $156,975
1,300 Added 6.5%
21,300 $1.61 Million
Q4 2020

Mar 12, 2021

BUY
$22.24 - $95.63 $444,799 - $1.91 Million
20,000 New
20,000 $1.77 Million

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.78B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Deka Bank Deutsche Girozentrale Portfolio

Follow Deka Bank Deutsche Girozentrale and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

News

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.